Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glenn F Pierce

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Application of a hemophilia mortality framework to the Emicizumab Global Safety DatabaseFlora Peyvandi, Johnny N Mahlangu, Steven W Pipe, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 8, 2024
Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia AEmily Symington, Savita Rangarajan, Will Lester, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 13, 2026
Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia APriyanka Raheja, Savita Rangarajan, Will Lester, et al.
Biologicals : Journal of the International Association of Biological Standardization|June 22, 2015
Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion proteinJustin McCue, Rashmi Kshirsagar, Keith Selvitelli, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2004
Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical useDan-ling Gu, Thanh Nguyen, Ana Maria Gonzalez, et al.
Plos One|February 4, 2016
Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B MiceGarabet G Toby, Tongyao Liu, Yang Buyue, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2005
Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulationJ Fraser Wright, Tannie Le, Joseph Prado, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 5, 2024
Development of the World Federation of Hemophilia Shared Decision-Making ToolDonna Coffin, Mark W Skinner, Courtney D Thornburg, et al.
Critical Reviews in Biotechnology|October 26, 2013
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsTimo Rath, Kristi Baker, Jennifer A Dumont, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 24, 2020
Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round TableGlenn F Pierce, K John Pasi, Donna Coffin, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Application of a hemophilia mortality framework to the Emicizumab Global Safety DatabaseFlora Peyvandi, Johnny N Mahlangu, Steven W Pipe, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 8, 2024
Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia AEmily Symington, Savita Rangarajan, Will Lester, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 13, 2026
Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia APriyanka Raheja, Savita Rangarajan, Will Lester, et al.
Biologicals : Journal of the International Association of Biological Standardization|June 22, 2015
Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion proteinJustin McCue, Rashmi Kshirsagar, Keith Selvitelli, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2004
Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical useDan-ling Gu, Thanh Nguyen, Ana Maria Gonzalez, et al.
Plos One|February 4, 2016
Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B MiceGarabet G Toby, Tongyao Liu, Yang Buyue, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2005
Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulationJ Fraser Wright, Tannie Le, Joseph Prado, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 5, 2024
Development of the World Federation of Hemophilia Shared Decision-Making ToolDonna Coffin, Mark W Skinner, Courtney D Thornburg, et al.
Critical Reviews in Biotechnology|October 26, 2013
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsTimo Rath, Kristi Baker, Jennifer A Dumont, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 24, 2020
Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round TableGlenn F Pierce, K John Pasi, Donna Coffin, et al.
Pageof 10